BioXcel Therapeutics, Inc. (BTAI) Social Stream



BioXcel Therapeutics, Inc. (BTAI): $2.79

0.03 (+1.09%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

BIOXCEL THERAPEUTICS INC (BTAI) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering BTAI.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-10 6 $140 $75 $101.375 $2.84 3469.54%
2021-12-16 7 $140 $75 $101.375 $2.84 3469.54%
2022-01-13 7 $140 $73 $99.75 $2.84 3412.32%
2022-02-01 7 $140 $73 $99.428 $2.84 3400.99%
2022-03-10 6 $140 $73 $99.428 $2.84 3400.99%
2022-03-18 6 $130 $73 $98 $2.84 3350.7%
2022-04-06 5 $130 $73 $98.5 $2.84 3368.31%
2022-04-08 5 $130 $75 $97.714 $2.84 3340.63%
2022-04-14 4 $134 $76 $102.166 $2.84 3497.39%
2022-04-25 4 $134 $76 $101.833 $2.84 3485.67%
2022-05-09 4 $134 $62 $90.5 $2.84 3086.62%
2022-05-10 4 $134 $20 $81.166 $2.84 2757.96%
2022-05-13 4 $134 $20 $76.571 $2.84 2596.16%
2022-05-23 4 $110 $20 $73.142 $2.84 2475.42%
2022-06-08 4 $110 $20 $71.714 $2.84 2425.14%
2022-07-07 5 $110 $19 $62.428 $2.84 2098.17%
2022-08-13 5 $110 $19 $61.571 $2.84 2067.99%
2022-09-17 5 $90 $19 $58 $2.84 1942.25%
2022-11-16 6 $85 $18 $52.625 $2.84 1752.99%
2022-12-01 8 $85 $16 $48.555 $2.84 1609.68%
2022-12-15 8 $85 $16 $49.222 $2.84 1633.17%
2023-01-03 8 $82 $16 $47.888 $2.84 1586.2%
2023-01-26 8 $82 $20 $49 $2.84 1625.35%
2023-01-30 8 $78 $20 $48.555 $2.84 1609.68%
2023-02-08 8 $78 $20 $48.777 $2.84 1617.5%
2023-02-21 8 $79 $20 $51 $2.84 1695.77%
2023-03-09 8 $79 $20 $51 $2.84 1695.77%
2023-03-10 8 $79 $22 $51.222 $2.84 1703.59%
2023-03-21 8 $78 $22 $49.666 $2.84 1648.8%
2023-03-31 8 $75 $22 $49.333 $2.84 1637.08%
2023-05-08 8 $75 $22 $49 $2.84 1625.35%
2023-05-10 8 $75 $22 $51.444 $2.84 1711.41%
2023-05-11 8 $75 $24 $51.666 $2.84 1719.23%
2023-06-06 8 $75 $24 $51.555 $2.84 1715.32%
2023-06-29 8 $75 $23 $49.333 $2.84 1637.08%
2023-07-03 8 $75 $23 $48.666 $2.84 1613.59%
2023-07-05 8 $75 $18 $43.444 $2.84 1429.72%
2023-08-14 8 $75 $18 $43.444 $2.84 1429.72%
2023-08-15 8 $75 $4 $38 $2.84 1238.03%
2023-08-28 8 $31 $4 $14.888 $2.84 424.23%

The Trend in the Analyst Price Target


Over the past 20 months, BTAI's average price target has gone down $84.86.

BTAI reports an average of 224.07% for its upside potential over the past 41 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2022-11-16 7 85 18 52.625 15.35 242.83%
2023-02-08 8 78 20 48.777 33.24 46.74%
2023-05-26 8 75 24 51.555 18.87 173.21%
2023-05-30 8 75 24 51.555 18.94 172.2%
2023-06-02 8 75 24 51.555 18.93 172.35%

BTAI Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2 4 0 4 0 0 8

The Trend in the Broker Recommendations


Over the past 20 months, BTAI's average broker recommendation rating worsened by 1.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for BTAI as an investment opportunity.

  • In the context of all US stocks, BIOXCEL THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is greater than 4425.05% of them.
  • To contextualize these metrics, consider that out of stocks in the small market cap category, BIOXCEL THERAPEUTICS INC's average analyst price target is greater than 4136.12% of them.
  • In terms of how BIOXCEL THERAPEUTICS INC fares relative to stocks in the small market cap category, note that its variance in analysts' estimates is lower than -3650.1% of that group.
  • BTAI has a higher number of analysts covering the stock than 3318.24% of stocks in the small market cap category.

In the Pharmaceutical Products industry, MBIO, ACET, and KZIA are the three stocks most similar to BIOXCEL THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.

Is BTAI a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!